

Richter further strengthens its presence in China

22 January 2016

Gedeon Richter Plc. ("Richter") announced today that it acquired from its partner, Rxmidas Pharmaceuticals Holdings Ltd. its outstanding 50% stake in Gedeon Richter Rxmidas Joint Venture Co. Ltd. following the setting up of a joint venture with an initial 50% share of equity announced in December 2010. Subsequent to the present acquisition, Richter now holds 100% of Gedeon Richter Rxmidas Joint Venture Co. Ltd., consequently will be in full charge of its contraceptive and OTC business in China. The financial terms of the agreement are undisclosed.

The current transaction is considered to be a further important step to underline Richter's commitment to expand its business in China, one of the fastest growing pharmaceutical markets.

About Gedeon Richter Plc.

Gedeon Richter Plc. (www.richter.hu), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe. Richter's consolidated sales were approximately EUR 1.1 billion (US\$ 1.5 billion), while its market capitalization amounted to EUR 2.1 billion (US\$ 2.5 billion) in 2014. The product portfolio of Richter covers almost all important therapeutic areas, including gynaecology, central nervous system, and cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter's original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the women's healthcare field worldwide. Richter is also active in biosimilar product development.

About Rxmidas

Rxmidas is a private company founded at the end of 2007 by experienced senior China executives. Rxmidas focuses on the sales/promotion and lifecycle management of drugs in China as well as on the development of a specialty drug pipeline for the Chinese Pharmaceutical market. Rxmidas is based in Shanghai and has a significant expertise concerning the Chinese Pharmaceutical market.

For further information:

Katalin Ördög, Investor Relations	+36 1 431 5680
Zsuzsa Beke, Public Relations	+36 1 431 4888